Skip to main content

Table 3 Chromatin-modifying agents under investigation for MPN therapy

From: Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies

Agent Brand Name Pharmaceutical company Mechanism of action Phase of study in MPN
Histone deacetylase inhibitors
LBH589 Panobinostat Novartis Class I/II HDAC inhibition I/II
HSP 90 inhibition
ITF2357 Givinostat Italfarmaco Class I/II HDAC inhibition II
HSP90 inhibition
Suberoylanilide hydroxamic acid Vorinostat Merck Class I/II HDAC inhibition None
HSP90 inhibition
DNA methyltransferase inhibitors
Azacitidine Vidaza Celgene DNA methyltransferase I inhibition Phase II
Decitabine Dacogen Eisai DNA methyltransferase I inhibition Phase II